OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.

Creative Commons License

Aydinlar E., Dikmen P., Kosak S., Kocaman A.

The journal of headache and pain, vol.18, no.1, pp.23, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.1186/s10194-017-0723-4
  • Journal Name: The journal of headache and pain
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.23
  • Keywords: Chronic migraine, Sleep quality, Headache, Analgesic, MIDAS, DASS-21, PREEMPT CLINICAL-PROGRAM, PLACEBO-CONTROLLED PHASE, CHRONIC DAILY HEADACHE, ANXIETY STRESS SCALES, EPISODIC MIGRAINE, OF-LIFE, BOTULINUM-TOXIN, PSYCHOMETRIC PROPERTIES, MEDICATION OVERUSE, DOUBLE-BLIND
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Background: OnabotulinumtoxinA (OnabotA) is considered effective in in patients with chronic migraine (CM) who failed on traditional therapies. This study was designed to evaluate the effect of OnabotA injection series on migraine outcome, negative emotional states and sleep quality in patients with CM.